FindTrial
Sign In

Comparison of blood levels of the protein Tenascin-C in healthy adults and adults with oral inflammation, precancerous oral conditions, and oral cancer.

Evaluation and comparison of Serum Tenascin-C levels in normal healthy individuals, oral inflammatory lesion, oral potentially malignant disorders and oral squamous cell carcinoma -A cross sectional study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/03/106420
Enrollment
160
Registered
2026-03-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C069- Malignant neoplasm of mouth, unspecified

Interventions

Intervention1: Nil: Nil Intervention2: Venipuncture sampling: 3-5 mL venous blood will be collected using a syringe and centrifuged to obtain serum for further analysis. Control Intervention1: Levels

Sponsors

NIL
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Normal Healthy Individuals with normal oral mucosa advised for routine blood investigation Oral Inflammatory Lesions patients advised for routine blood investigation Clinical and Histopathologically Confirmed cases of Oral Potentially Malignant Disorders patients advised for routine blood investigation Clinical and Histopathologically Confirmed cases of Oral Squamous cell carcinoma patients advised for routine blood investigation

Exclusion criteria

Exclusion criteria: Patients with systemic diseases, inflammatory systemic diseases, autoimmune disorders or any other chronic infections. Individuals on medications particularly steroids, immunosuppressive and anti-inflammatory. Patients with previous or ongoing chemotherapy/radiotherapy.

Design outcomes

Primary

MeasureTime frame
Measuring serum Tenascin-C (TN-C) levels may show changes from normal oral mucosa to oral inflammation, potentially malignant disorders, and oral cancer. If significant variation is found, TN-C may help in early diagnosis and prognosis of oral squamous cell carcinoma. It may also be used in combination with other blood markers and help monitor response to treatment.Timepoint: 6 months 1 year 2 year—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Deepa R Mane

KAHER KLE VK Institute of dental sciences

deeparajeshmane@gmail.com9743542301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026